1. DOP42 Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study. (21st January 2022) Authors: Danese, S; Panaccione, R; D'Haens, G; Peyrin-Biroulet, L; Schreiber, S; Kobayashi, T; Gawdis-Wojnarska, B; Korga, P; Aguilar, H; Sharkey, B; Sreih, A; Radosti, C; Patel, A; Canavan, J; Rubin, D Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i091 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. (27th September 2022) Authors: Van Vollenhoven, R; Pike, M; Merrill, JT; Morand, E; Werth, VP; Hobar, C; Delev, N; Shah, V; Sharkey, B; Wegman, T; Catlett, I; Banerjee, S; Singhal, S Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗